IMUNON R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer Treatment
IMUNON (Nasdaq: IMNN) will host an R&D Day on Monday, November 10, 2025 at 8:00 a.m. ET in New York City with a live webcast option. The event features principal investigators discussing clinical progress for IMNN-001, a DNA-mediated IL-12 immunotherapy in Phase 3 development for advanced ovarian cancer, plus Phase 2 MRD results and Phase 3 statistical design.
Speakers include investigators from Washington University, MD Anderson, Berry Consultants, and IMUNON leadership covering OVATION 3/OVATION 2 data, MRD trial immune activation, trial design, enrollment momentum, and near-term clinical milestones. Registration is required to attend in person or virtually.
IMUNON (Nasdaq: IMNN) terrà una giornata R&D il lunedì 10 novembre 2025 alle ore 8:00 Eastern Time a New York City con opzione di webcast in diretta. L'evento vedrà i ricercatori principali discutere i progressi clinici per IMNN-001, una immunoterapia IL-12 mediata da DNA in sviluppo di fase 3 per il cancro ovarico avanzato, oltre ai risultati di Fase 2 MRD e al design statistico di Fase 3.
Relatori includono ricercatori della Washington University, MD Anderson, Berry Consultants e la leadership di IMUNON, che copriranno i dati OVATION 3/OVATION 2, l'attivazione immunitaria nel trial MRD, il design dello studio, l'entusiasmo per l'enrollment e le prossime milestone cliniche. La registrazione è necessaria per partecipare in persona o virtualmente.
IMUNON (Nasdaq: IMNN) organizará un día de I+D el lunes 10 de noviembre de 2025 a las 8:00 a.m. hora del Este en la ciudad de Nueva York, con opción de webcast en vivo. El evento contará con investigadores principales que discutirán el progreso clínico de IMNN-001, una inmunoterapia IL-12 mediada por ADN en desarrollo de fase 3 para el cáncer de ovario avanzado, además de resultados de la Fase 2 MRD y del diseño estadístico de la Fase 3.
Entre los ponentes se encuentran investigadores de la Universidad de Washington, MD Anderson, Berry Consultants y el liderazgo de IMUNON, que cubrirán datos OVATION 3/OVATION 2, la activación inmunitaria del ensayo MRD, el diseño del ensayo, el impulso de la inscripción y los hitos clínicos a corto plazo. Se requiere registro para asistir en persona o virtualmente.
IMUNON (나스닥: IMNN)은 2025년 11월 10일 월요일 오전 8:00(동부 표준시)에 뉴욕시에서 연구개발 데이를 주최하며 라이브 웹캐스트 옵션이 있습니다. 이 행사는 고급 자궁암에 대한 DNA 매개 IL-12 면역치료제인 IMNN-001의 3상 개발과 함께 제2상 MRD 결과 및 3상 통계 설계에 대해 임상 연구책임자들이 논의합니다.
발표자에는 워싱턴 대학교, MD 앤더슨 암 센터, Berry Consultants, 그리고 IMUNON 경영진이 포함되며 OVATION 3/OVATION 2 데이터, MRD 연구의 면역 활성화, 시험 설계, 등록 추세 및 단기간 임상 이정표를 다룹니다. 현장 참가 또는 가상 참석을 원하시면 등록이 필요합니다.
IMUNON (Nasdaq : IMNN) organisera une journée R&D le lundi 10 novembre 2025 à 8h00, heure de l'Est à New York, avec une option de webcast en direct. L'événement réunit des chercheurs principaux qui discuteront des progrès cliniques concernant IMNN-001, une immunothérapie IL-12 médiée par ADN en développement de phase 3 pour le cancer de l'ovaire avancé, ainsi que les résultats de la phase 2 MRD et le design statistique de la phase 3.
Les intervenants comprennent des chercheurs de la Washington University, MD Anderson, Berry Consultants et la direction d'IMUNON, couvrant les données OVATION 3/OVATION 2, l'activation immunitaire du MRD, la conception de l'essai, l'élan de l'inscription et les jalons cliniques à court terme. L'inscription est requise pour assister sur place ou virtuellement.
IMUNON (Nasdaq: IMNN) wird am Montag, dem 10. November 2025 um 08:00 Uhr Eastern Time in New York City eine R&D-Tagung abhalten, mit der Option auf einen Live-Webcast. Die Veranstaltung wird Hauptuntersucher vorstellen, die den klinischen Fortschritt von IMNN-001, einer DNA-vermittleten IL-12-Immuntherapie in der dritten Phase zur fortgeschrittenen Ovarialkarzinomentwicklung, sowie Ergebnisse der Phase 2 MRD und das statistische Design der Phase 3 diskutieren.
Zu den Sprechern gehören Forscher der Washington University, MD Anderson, Berry Consultants und die Führungsebene von IMUNON, die OVATION 3/OVATION 2-Daten, die Immunaktivierung der MRD-Studie, Studiendesign, Einschreibungsdynamik und kurzfristige klinische Meilensteine abdecken. Eine Registrierung ist erforderlich, um persönlich oder virtuell teilzunehmen.
IMUNON (بورصة ناسداك: IMNN) ستستضيف يوم البحث والتطوير يوم الإثنين 10 نوفمبر 2025 الساعة 8:00 صباحاً بتوقيت شرق الولايات المتحدة في مدينة نيويورك مع خيار البث المباشر عبر الويب. يضم الحدث متحدثين رئيسيين سيناقشون التقدم السريري لـ IMNN-001، العلاج المناعي IL-12 المعتمد على الحمض النووي في التطوير من المرحلة 3 لسرطان المبيض المتقدم، بالإضافة إلى نتائج المرحلة 2 MRD وتصميم الإحصاءات للمرحلة 3.
سيشمل المتحدثون باحثين من جامعة ويسكونسن، ومركز MD Anderson، ومستشاري Berry، وقيادة IMUNON الذين سيغطيون بيانات OVATION 3/OVATION 2، وتفعيل المناعة في تجربة MRD، وتصميم التجربة، وزخم التسجيل، والمعالم السريرية القريبة الأجل. التسجيل مطلوب للحضور شخصياً أو عبر الإنترنت.
- None.
- None.
Insights
R&D Day previews Phase 3 and Phase 2 clinical data presentations on
IMUNON is presenting investigators' perspectives on its DNA‑mediated IL‑12 therapy IMNN-001, including discussion of the Phase 3 OVATION 3 program and Phase 2 minimal residual disease study; presenters include principal investigators and the company’s chief medical lead, which creates a direct channel for clinical detail to reach stakeholders.
Key dependencies and risks include the content and statistical strength of the cited OVATION 2 "survival benefits" and the Phase 2 MRD immune‑activation results; the regulatory path hinges on the Phase 3 design and accumulated endpoints described by the listed statistician. The event itself does not change trial outcomes; it only discloses investigator interpretation and trial metrics.
Concrete items to watch: the numeric survival and safety data disclosed at the
Investors and stakeholders invited to attend in person in New York City or via live webcast on Monday, November 10th at 8:00 a.m. ET
LAWRENCEVILLE, N.J., Nov. 07, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, will host an R&D Day on Monday, November 10, 2025 at 8:00 a.m. ET in New York City featuring in-depth discussions with experts including principal investigators leading the Phase 3 OVATION 3 clinical trial and Phase 2 minimal residual disease (MRD) trial of IMNN-001, a novel IL-12 immunotherapy in development for the treatment of women with advanced ovarian cancer.
“This is an opportunity to hear directly from the investigators driving IMNN-001 clinical progress forward—physicians who see firsthand the urgent need for new ovarian cancer treatment options and the potential clinical impact of our novel IMNN-001 immunotherapy,” said Stacy R. Lindborg, Ph.D., president and chief executive officer of IMUNON. “The data and insights shared will be consequential for understanding the future of ovarian cancer treatment and how we are leading the effort to bring the first advance in the standard of care that could transform frontline treatment, which has not seen innovation for about 30 years.”
The event will include presentations from:
- Premal H. Thaker, M.D. (Washington University School of Medicine) – Unmet need and OVATION 2 trial data including survival benefits
- Amir A. Jazaeri, M.D. (MD Anderson Cancer Center) – Phase 2 MRD study results and immune activation mechanism overview
- Giorgio Paulon, Ph.D. (Berry Consultants, LLC) – Phase 3 trial statistical design and path to approval
- Douglas V. Faller, M.D., Ph.D. (IMUNON) – Phase 3 trial enrollment momentum and clinical milestones
To register to attend the event in person or virtually, please RSVP by clicking here.
About IMUNON
IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response.
The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials including one Phase 2 clinical trial (OVATION 2) and is currently conducting a Phase 3 clinical trial (OVATION 3). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that forward-looking statements in this news release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding the timing of enrollment of the Company’s clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company’s products, if approved, the potential efficacy and safety profile of our product candidates, and the Company’s plans and expectations with respect to its development programs more generally, are forward-looking statements. We generally identify forward-looking statements by using words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON’s filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.
Contacts:
| Media | Investors |
| Jenna Urban | Peter Vozzo |
| CG life | ICR Healthcare |
| 212-253-8881 | 443-213-0505 |
| jurban@cglife.com | peter.vozzo@icrhealthcare.com |
FAQ
When and where is IMUNON's R&D Day for IMNN-001?
What clinical programs for IMNN-001 will be discussed at IMUNON's R&D Day?
Which investigators will present OVATION 2 and MRD data at the IMUNON event?
How can investors register to attend IMUNON's R&D Day for IMNN (Nasdaq: IMNN)?
What trial design and approval pathway details will IMUNON present for IMNN-001?
Will IMUNON discuss enrollment and near-term milestones for IMNN-001 at the R&D Day?
